Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04332549
Other study ID # SDO-006-20-01
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date April 27, 2020
Est. completion date January 28, 2021

Study information

Verified date May 2020
Source Sun Pharma Advanced Research Company Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, multi center, open label, two-period, single dose, crossover study to evaluate the bioavailability and safety of Paclitaxel Injection Concentrate for Suspension in Locally Recurrent or Metastatic Breast Cancer subjects.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 28, 2021
Est. primary completion date January 28, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. The subject has given written, informed consent (or legally acceptable representative /impartial witness when applicable) and is available for the duration of study

2. Histologically or cytologically confirmed diagnosis of breast cancer with adequate documentation of prior therapy with an anthracycline unless clinically contraindicated

3. Locally recurrent or MBC for which taxane-based therapy is an appropriate treatment option

4. Male or female aged greater than equal to 18 years

5. ECOG performance status less than equal to 1

6. Estimated life expectancy of at least 12 weeks

7. Adequate organ and immune system function as indicated by the following laboratory values, obtained less than equal to 2 weeks prior to dosing for Period 1 and Period 2:

8. Any chemotherapy, targeted therapy, major surgery, or irradiation must have been completed at least 4 weeks before enrollment (6 weeks for mitomycin C or nitrosurea); immune therapy or hormonal therapy (except palliative bisphosphonate therapy for bone pain) must be completed 2 weeks before enrollment and subjects must have recovered from all toxicities incurred as a result of previous therapy except alopecia; use of targeted therapy or antibody therapy should have been completed for at least 5 half-lives of the respective therapy before enrollment. Use of narcotic analgesics such as dihydrocodeine and medicinal herbs such as St. John's Wort, which may act as inhibitors/inducers of CYP2C8 and CYP3A4, must have been discontinued at least 2 weeks and 4 weeks respectively before enrollment

9. Subjects of child bearing potential must practice an acceptable method of birth control as judged by the investigator

- Medically acceptable methods of birth control include the use of either a contraceptive implant or a contraceptive injection (e.g., Depo-Provera™) or an intrauterine device, same sex partner or vasectomized partner or an oral contraceptive taken continually within the past three months and which the subject agrees to continue using during the study

- To adopt another birth control method, or a double-barrier method which consists of a combination of any two of the following:

diaphragm, cervical cap, condom, or a spermicide at least 2 months prior to study entry and must continue to use contraception for the duration of the study

10. Female subjects who are postmenopausal for at least 1 year as per investigator's discretion, or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)

11. Male subjects enrolled in the trial cannot father a child and are advised to prevent passage of semen to their sexual partner during intercourse using acceptable methods as judged by the investigator for the duration of the study

12. Females subjects of child-bearing potential must have a negative urine pregnancy test

13. Female subjects must be non-lactating and non-breastfeeding

14. Subject must be willing and able to comply with scheduled visits, treatment plan and laboratory testing.

Exclusion Criteria:

1. Known hypersensitivity to the study drug or their excipients (cholesteryl sulfate, caprylic acid, polyvinylpyrrolidone, ethanol, polyethylene glycol)

2. Inability to undergo venipuncture and/or tolerate venous access

3. Presence of clinically symptomatic active CNS metastases, including leptomeningial involvement, requiring steroid or radiation therapy

4. Pre-existing clinically significant peripheral neuropathy (Grade 2 or higher according to CTCAE, Version 5.0)

5. Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study or confound the study

6. Presence of pleural/ascitic fluid which cannot be definitively treated prior to dosing and during the PK blood draws in each period (Period 1 and Period 2) and if there is re-accumulation of fluid (greater than 5%) greater than 2 weeks after definitive management

7. Positive laboratory exclusion test (HIV, HBsAg, or HCV)

8. Treatment with investigational agents or participation in a clinical trial within 30 days of study entry

9. Failure of prior taxane therapy for metastatic disease or for adjuvant therapy within previous 6 months of screening visit

10. Subjects taking concurrent medications that may act as inhibitors/inducers of CYP2C8 and CYP3A4 within 2 weeks of screening and during Periods 1 and 2

11. Evidence or history of bleeding diathesis or coagulopathy within 6 months prior to screening visit

12. Uncontrolled cardiac disease, including: congestive heart failure (CHF) > Class II per New York Heart Association (NYHA), history of hypertensive crisis

13. Active clinical infection which in the treating investigator's opinion renders the subject ineligible or can confound the study

14. Serious non-healing wound, ulcer or bone fracture

15. Unresolved toxicity higher than CTCAE Version 5.0 Grade 1 (excluding alopecia, anemia) attributed to any prior therapy/procedure

16. History of gastrointestinal perforation within 6 months prior to screening visit.

Study Design


Intervention

Drug:
PICS (Reconstitution Method 1 or 2)
dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS

Locations

Country Name City State
India SPARC Site 21 Ahmadabad Gujarat
India SPARC Site 9 Aurangabad Maharashtra
India SPARC Site 10 Bangalore Karnataka
India SPARC Site 13 Bangalore Karnataka
India SPARC Site 18 Bangalore Karnataka
India SPARC Site 4 Bangalore Karnataka
India SPARC Site 6 Gujrat Vadodara
India SPARC Site 20 Khorda Orissa
India SPARC Site 8 Kolhapur Maharashtra
India SPARC Site 7 Lucknow Uttar Pradesh
India SPARC Site 14 Madurai Tamil Nadu
India SPARC Site 1 Nagpur Maharashtra
India SPARC Site 17 Nagpur Maharashtra
India SPARC Site 2 Nagpur Maharashtra
India SPARC Site 19 Nashik Maharashtra
India SPARC Site 3 Nashik Maharashtra
India SPARC Site 15 Pune Maharashtra
India SPARC Site 16 Pune Maharashtra
India SPARC Site 5 Pune Maharashtra
India SPARC Site 11 Sangli Maharashtra
India SPARC Site 22 Surat Gujarat
India SPARC Site 12 Visakhapatnam Andhra Pradesh

Sponsors (1)

Lead Sponsor Collaborator
Sun Pharma Advanced Research Company Limited

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum observed plasma concentration Plasma 8 weeks
Primary area under the plasma concentration versus time curve, from time 0 to the last measurable concentration 8 weeks
Primary area under the plasma concentration versus time curve from time 0 to infinity 8 weeks
Primary Incidence of Treatment-Emergent Adverse Events shall be coded per CTCAE, Version 5.0 8 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2